science
Talawar Therapeutics to list publicly through reverse merger with JATT II Acquisition Corp and $225 million financing
@statnews reported that Talawar Therapeutics plans to go public through a reverse merger with JATT II Acquisition Corp. The transaction includes a $225 million PIPE financing. The company said the funds will support its lead program through mid-stage clinical testing.
manilatimes.netAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Talawar Therapeutics plans to go public via a reverse merger with JATT II Acquisition Corp. The deal includes a $225 million PIPE financing, @statnews reported on June 29, 2026. Talawar Therapeutics stated that the financing will fund its lead program through mid-stage clinical testing.
The announcement appeared in STAT's The Readout newsletter, written by biotech correspondent Meghana Keshavan. The reverse merger structure allows the company to list shares without a traditional initial public offering process.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
